Publications

  1. Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, Slack GW, Smedby KE, Ansell SM, Link BK, Cerhan JR, Relander T, Savage KJ, Feldman AL. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. J Clin Oncol. 2017 Oct 26; JCO2017738195 [Epub ahead of print]
    View PubMed
  2. Hu G, Dasari S, Asmann YW, Greipp PT, Knudson RA, Benson HK, Li Y, Eckloff BW, Jen J, Link BK, Jiang L, Sidhu JS, Wellik LE, Witzig TE, Bennani NN, Cerhan JR, Boddicker RL, Feldman AL. Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia. 2017 Oct 13 [Epub ahead of print]
    View PubMed
  3. Bennani NN, Ansell SM. Peripheral T-cell lymphomas: very little good, mainly the bad and the ugly. Leuk Lymphoma. 2017 Oct; 58 (10):2273-2274 Epub 2017 June 02
    View PubMed
  4. Pedersen MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, Bedroske PP, Luoma IM, Sattler CA, Boddicker RL, Bennani NN, Norgaard P, Moller MB, Steiniche T, d'Amore F, Feldman AL. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood. 2017 Jul 27; 130: (4)554-557.
    View PubMed
  5. Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. Am J Hematol. 2017 May; 92: (5)448-453.
    View PubMed
  6. Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: B-cell non-Hodgkin lymphomas. Expert Rev Hematol. 2017 May; 10: (5)405-415.
    View PubMed
  7. Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol. 2017 Mar; 10: (3)239-249.
    View PubMed
  8. Bennani-Baiti N, Baltzer PA. Diagnostic Performance of Breast Magnetic Resonance Imaging in Non-Calcified Equivocal Breast Findings: Results from a Systematic Review and Meta-Analysis. PLoS One.2016;11(8)e0160346.
  9. Bennani-Baiti N, Thanarajasingam G, Ansell S. Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma. Expert Rev Clin Immunol. 2016 Jun; 12: (6)673-9.
    View PubMed
  10. Bennani-Baiti N, Ansell S, Feldman AL. Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management. Expert Rev Hematol. 2016; 9: (2)137-50.
    View PubMed
  11. Thanarajasingam G, Bennani NN, Nowakowski GS. Individualized Treatment of Diffuse Large B-cell Lymphoma— The Evolving Role of Molecular-subtype-specific Therapy Oncology & Hematology Review.2015 Nov 2;11:(2):113-4.
  12. Bennani-Baiti B, Yadav S, Flynt L, Bennani-Baiti N, Bennani NN. Value of positron emission tomography in diagnosing subcutaneous panniculitis-like T-cell lymphoma. J Clin Oncol. 2015 Apr 1; 33: (10)1216-7.
    View PubMed
  13. Bennani-Baiti N, Bennani-Baiti IM. Cancer Bioinformatic Methods to Infer Meaningful Data From Small-Size Cohorts. Cancer Inform. 2015; 14:131-9.
    View PubMed
  14. Shrotriya S, Walsh D, Bennani-Baiti N, Bennani NN, Thomas S, Lorton C. C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS One. 2015; 10: (12)e0143080.
    View PubMed
  15. Yadav S, Bennani NN. Renal cell carcinoma metastasis to the thyroid: How long is long enough? Acta Oncologica.2014 Aug 25;53:(9):1277-8.
  16. Sakruti S, Bennani NN, Thota S, Garje R, Fawole A, Elson P, Haddad A, Spiro T, Daw H. Diffuse large B cell lymphoma: role of MYC, BCL2, BCL6 protein expression and translocations Blood.2013 Nov 15;122:(21):5055.
  17. Shrotriya S, Walsh D, Bennani NN. C-Reactive Protein as a Prognostic Indicator in Adult Solid Tumors: A Systematic Review Journal of Pain and Symptom Management .2013 Feb ;45:(2):452-3.
  18. Bennani-Baiti N, Bennani NN, Daw HA, Cotta C, Martin P, Mitchell KW, Ambinder RF, Macklis R, Pollock R, Spiro T. Low-grade follicular lymphoma of the small intestine: a challenge for management. Semin Oncol. 2011 Dec; 38: (6)714-20.
    View PubMed
  19. Bennani NN, Walsh D. Animal models of the cancer anorexia–cachexia syndrome Support Care in Cancer.2011 Sep ;19:(9):1451-63.
  20. Bennani NN, Daw H. Primary Hyperfibrinolysis in Liver Disease: A Critical Review Clinical Advances in Hematology and Oncology.2001 Mar;9:(3):250-2.
  21. Davis M, Bennani NN, Seyidova-Khoshknabi D, Lagman R, Karafa M, Walsh D. Phase Angle is a Better Predictor of Survival than Muscle Mass in Advanced Cancer Journal of Pain and Symptom Management.2010 Feb 2;39:(2):336-7.
  22. Bennani NN, Walsh D. What is cancer anorexia cachexia syndrome? a historical perspective The Journal of Royal College of Physicians of Edinburgh.2009 Sep;39:(3):257-62.
  23. Seyidova-Khoshknabi D, Bennani NN, Kirkova J, Lasheen W, Davis M, Walsh D, Lagman R, LeGrand S. Insomnia in Advanced Cancer Journal of Pain and Symptom Management .2009 Mar 9;37:(3):469.
  24. Bennani NN, Walsh D. C-reactive protein as a prognosis indicator in solid tumors: A systematic review Supportive Care in Cancer.2009 Jan;17:857-1039.
  25. Davis M, Bennani NN, Seyidova-Khoshknabi D, Lagman R, Karafa M, Walsh D. Phase Angle is a Better Predictor of Survival Than Muscle Mass in Advanced Cancer Supportive Care in Cancer.2009 Jan;17:857–1039.
  26. Bennani NN, Davis M. Cytokines and cancer anorexia cachexia syndrome American Journal of Hospice and Palliative Medicine.2008 Nov ;25:(5):407-11.
  27. Seyidova-Khoshknabi D, Bennani NN, Kirkova J, Lasheen W, Davis M, Walsh D, Lagman R, LeGrand S. Insomnia in Advanced Cancer Supportive Care in Cancer.2008 Aug 1;16:(6):718.
  28. Bennani NN, Davis M, Walsh D. Cachexias: a 2007 state of the art review of the metabolic and biochemical abnormalities in different clinical models of cachexia Supportive Care in Cancer.2007 Dec 6;15:(6):773-4.
  29. Bennani NN, Walsh D, Davis M. Animal models for cancer cachexia: what are the options? Supportive Care in Cancer.2007 Dec 6;15:(6):773.
  30. Yin L, Bennani NN, Powell CT. Phorbol Ester-induced apoptosis of C4-2 cells requires both a unique and a redundant protein kinase C signaling pathway Journal of Biological Chemistry.2005 Feb 18;280:(7):5533-41.